Chimeric Antigen Receptor T-Cell (CAR-T) is a novel treatment for patients with cancer. The use of this technology is expected to grow and evolve over the coming years. CAR-T therapy is licensed as a drug and is therefore subject to the standard HSE drug reimbursement assessment process. There are technical processes required to support the use of CAR-T therapy which differentiates this therapy from other systemic anti-cancer therapies.
The NCCP designated paediatric CAR-T centre is CHI @ Crumlin. The NCCP designated adult CAR-T centres are:
- St. James’s Hospital (SJH)
- University Hospital Galway (UHG) (Target to be operational in 2025)
Documents:
